ArticleACS central science2025
Multicatalysis-Enabled Multicomponent Reactions Generate a PTP1B Inhibitor.
Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multicomponent reactions for protein tyrosine phosphatase inhibitors.Molecular diversity · 2026Review
- Catalyzed Enantioselective Organic Synthesis.ACS central science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multicomponent reactions are powerful tools for expanding the chemical space in drug discovery, yet achieving selectivity remains a formidable challenge. Here, we introduce a multicatalytic strategy to enable a multicomponent reaction, utilizing a cooperative system of rhodium, copper, Brønsted acid, and magnesium catalysts. This approach achieves excellent chemo-, diastereo-, and enantioselectivity (up to 99% yield, >20:1 dr, and 99% ee). Mechanistic studies, combining experimental and computational analyses, reveal a cascade sequence involving cyclopropenation, desilylation, cyclization, isomerization, aldol addition, and hydrolysis. This highly selective method exhibits broad substrate generality, producing 50 diverse CHBOs. Virtual screening and rapid biological evaluation led to the discovery of (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.